Table 3. Chemotherapy trials of neoadjuvant chemotherapy for colorectal cancer liver metastases.

	Schedule	Selected patients	No. of patients	RR (%)	R0 resection (%)
Cetuximab plus doublets	Cetuximab+FOLFIRI (Van Cutsem, et al, 2009)	No	132	46.9	4.8
	Cetuximab+FOLFOX4 (Bokemeyer et al, 2009)	No	169	46.0	4.7
	Cetuximab+FOLFOX or FOLFIRI (Folprecht et al, 2010)	Yes	111	85.0 (Oxa)-66.0 (CPT)	34
Triplets	FOLFOXIRI (Falcone et al, 2007)	No	39	66	36
	FOLFOXIRI (De la Cámara et al, 2004)	Yes	39	64	43
	FOLFOXIRI (Ychou et al, 2008)	Yes	34	70	26
Monoclonal antibody plus triplets	Cetximab+chrono-IFLO (Garufi et al, present study)	Yes	43	79.1	60
	Bevacizumab+FOLFOXIRI (Masi et al, 2010)	No	30	80	40

Abbreviations: CPT=irinotecan; Oxa=oxaliplatin; RR=response rate; R0 resection=radical resection.